Literature DB >> 20439843

Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes.

S Gilman1, R A Koeppe, B Nan, C-N Wang, X Wang, L Junck, R D Chervin, F Consens, A Bhaumik.   

Abstract

OBJECTIVES: Cholinergic projections to cerebral cortical and subcortical regions are decreased in Parkinson disease (PD), but not evaluated in the parkinsonian syndromes of multiple system atrophy (MSA-P) and progressive supranuclear palsy (PSP). We studied cholinergic innervation in these disorders as compared to age-appropriate normal control subjects.
METHODS: We used PET with [(11)C]PMP to measure acetylcholinesterase (AChE) activity in multiple cerebral cortical and subcortical regions. We studied 22 normal controls, 12 patients with PD, 13 patients with MSA-P, and 4 patients with PSP.
RESULTS: We found significantly decreased AChE activity in most cerebral cortical regions in PD and MSA-P, and a similar but nonsignificant decrease in PSP. No differences were found between PD and MSA-P. Significantly decreased AChE activity was found in PD in striatum, cerebellum, and thalamus, with a marginally significant decrease in mesencephalon and no change in pons. Significantly greater declines in AChE activity in all subcortical regions were seen in MSA-P and PSP vs in PD. Decreased AChE activity in brainstem and cerebellum of all 3 disorders correlated with disturbances of balance and gait.
CONCLUSIONS: Cerebral cortical cholinergic activity is decreased to a similar level in Parkinson disease (PD), parkinsonian syndromes of multiple system atrophy (MSA-P), and progressive supranuclear palsy (PSP) as compared to normal controls. Subcortical cholinergic activity is significantly more decreased in MSA-P and PSP than in PD. The more substantial decrease reflects greater impairment in the pontine cholinergic group, which is important in motor activity, particularly gait. These differences may account for the greater gait disturbances in the early stages of MSA-P and PSP than in PD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20439843      PMCID: PMC2871002          DOI: 10.1212/WNL.0b013e3181dc1a55

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  39 in total

1.  Kinetic modeling of N-[11C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography trace for measurement of acetylcholinesterase activity in human brain.

Authors:  R A Koeppe; K A Frey; S E Snyder; P Meyer; M R Kilbourn; D E Kuhl
Journal:  J Cereb Blood Flow Metab       Date:  1999-10       Impact factor: 6.200

2.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

Review 3.  Alzheimer's disease: a disorder of cortical cholinergic innervation.

Authors:  J T Coyle; D L Price; M R DeLong
Journal:  Science       Date:  1983-03-11       Impact factor: 47.728

4.  Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease.

Authors:  I Nakano; A Hirano
Journal:  Ann Neurol       Date:  1984-05       Impact factor: 10.422

5.  Perceptual motor dysfunction in Parkinson's disease: a deficit in sequential and predictive voluntary movement.

Authors:  Y Stern; R Mayeux; J Rosen; J Ilson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-02       Impact factor: 10.154

6.  Cognitive deficits in the early stages of Parkinson's disease.

Authors:  A J Lees; E Smith
Journal:  Brain       Date:  1983-06       Impact factor: 13.501

7.  Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases.

Authors:  J M Candy; R H Perry; E K Perry; D Irving; G Blessed; A F Fairbairn; B E Tomlinson
Journal:  J Neurol Sci       Date:  1983-05       Impact factor: 3.181

8.  Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.

Authors:  Nicolaas I Bohnen; Daniel I Kaufer; Larry S Ivanco; Brian Lopresti; Robert A Koeppe; James G Davis; Chester A Mathis; Robert Y Moore; Steven T DeKosky
Journal:  Arch Neurol       Date:  2003-12

9.  Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease.

Authors:  T Arendt; V Bigl; A Arendt; A Tennstedt
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

10.  Basal forebrain neurons in the dementia of Parkinson disease.

Authors:  P J Whitehouse; J C Hedreen; C L White; D L Price
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

View more
  57 in total

Review 1.  The neurobiology of falls.

Authors:  Alfonso Fasano; Meir Plotnik; Francesco Bove; Alfredo Berardelli
Journal:  Neurol Sci       Date:  2012-06-05       Impact factor: 3.307

2.  Co-occurrence of parkinsonism and dementia in clinical practice: relevant differential diagnoses.

Authors:  I Liepelt-Scarfone; M Jamour; W Maetzler
Journal:  Z Gerontol Geriatr       Date:  2012-01       Impact factor: 1.281

Review 3.  Dichotomy between motor and cognitive functions of midbrain cholinergic neurons.

Authors:  Nadine K Gut; Juan Mena-Segovia
Journal:  Neurobiol Dis       Date:  2018-09-10       Impact factor: 5.996

4.  Cerebellar Volume and Executive Function in Parkinson Disease with and without Freezing of Gait.

Authors:  Peter S Myers; Marie E McNeely; Jonathan M Koller; Gammon M Earhart; Meghan C Campbell
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

Review 5.  Treatment of multiple system atrophy - the past, present and future.

Authors:  Haiyan Yu; Xiaoling Yuan; Lifeng Liu; Tian Wang; Dianrong Gong
Journal:  Am J Clin Exp Immunol       Date:  2018-10-05

Review 6.  Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group.

Authors:  Iva Stankovic; Florian Krismer; Aleksandar Jesic; Angelo Antonini; Thomas Benke; Richard G Brown; David J Burn; Janice L Holton; Horacio Kaufmann; Vladimir S Kostic; Helen Ling; Wassilios G Meissner; Werner Poewe; Marija Semnic; Klaus Seppi; Atsushi Takeda; Daniel Weintraub; Gregor K Wenning
Journal:  Mov Disord       Date:  2014-04-18       Impact factor: 10.338

Review 7.  Neuroimaging of mobility in aging: a targeted review.

Authors:  Roee Holtzer; Noah Epstein; Jeannette R Mahoney; Meltem Izzetoglu; Helena M Blumen
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-04-16       Impact factor: 6.053

8.  The cortical cholinergic system contributes to the top-down control of distraction: Evidence from patients with Parkinson's disease.

Authors:  Kamin Kim; Martijn L T M Müller; Nicolaas I Bohnen; Martin Sarter; Cindy Lustig
Journal:  Neuroimage       Date:  2017-12-19       Impact factor: 6.556

9.  Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.

Authors:  Tommaso Schirinzi; Giulia Maria Sancesario; Giulia Di Lazzaro; Simona Scalise; Vito Luigi Colona; Paola Imbriani; Nicola Biagio Mercuri; Sergio Bernardini; Anthony E Lang; Antonio Pisani
Journal:  J Neural Transm (Vienna)       Date:  2018-06-14       Impact factor: 3.575

10.  New MRI Biomarkers Advance the Characterization of Parkinson Disease.

Authors:  David A Ziegler; Suzanne Corkin
Journal:  Eur Neurol Rev       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.